Biologic drugs as analgesics for the management of osteoarthritis

Chessell, 2012, Biologics: the next generation of analgesic drugs?, Drug Discov Today, 17, 875, 10.1016/j.drudis.2012.03.005 Hochberg, 2012, American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee, Arthritis Care Res (Hoboken), 64, 465, 10.1002/acr.21596 Westacott, 1996, Cytokines in osteoarthritis: mediators or markers of joint destruction?, Semin Arthritis Rheum, 25, 254, 10.1016/S0049-0172(96)80036-9 Simão, 2014, Soluble TNF receptors are produced at sites of inflammation and are inversely associated with self-reported symptoms (WOMAC) in knee osteoarthritis, Rheumatol Int, 34, 1759, 10.1007/s00296-014-3016-0 Leung, 2010, TNF-alpha and neuropathic pain—a review, J Neuroinflammation, 7, 27, 10.1186/1742-2094-7-27 Mantyh, 2011, Antagonism of nerve growth factor-TrkA signaling and the relief of pain, Anesthesiology, 115, 189, 10.1097/ALN.0b013e31821b1ac5 Oddiah, 1998, Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder, Neuroreport, 9, 1455, 10.1097/00001756-199805110-00038 Kumar, 2012, NGF—the TrkA to successful pain treatment, J Pain Res, 5, 279, 10.2147/JPR.S33408 Pezet, 2006, Neurotrophins: mediators and modulators of pain, Annu Rev Neurosci, 29, 507, 10.1146/annurev.neuro.29.051605.112929 Maliartchouk, 1997, Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands, J Neurosci, 17, 6031, 10.1523/JNEUROSCI.17-16-06031.1997 Eibl, 2012, Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor, Neurochem Int, 61, 1266, 10.1016/j.neuint.2012.10.008 Kawamoto, 2002, Nerve growth factor activates mast cells through the collaborative interaction with lysophosphatidylserine expressed on the membrane surface of activated platelets, J Immunol, 168, 6412, 10.4049/jimmunol.168.12.6412 Petersen, 1998, Nerve growth factor regulates the expression of bradykinin binding sites on adult sensory neurons via the neurotrophin receptor p75, Neuroscience, 83, 161, 10.1016/S0306-4522(97)00374-6 Kapoor, 2011, Role of proinflammatory cytokines in the pathophysiology of osteoarthritis, Nat Rev Rheumatol, 7, 33, 10.1038/nrrheum.2010.196 Gasparyan, 2011, Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors, Rheumatol Int, 31, 1409, 10.1007/s00296-011-1999-3 Verbruggen, 2012, Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification, Ann Rheum Dis, 71, 891, 10.1136/ard.2011.149849 Chevalier, 2015, Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial, Ann Rheum Dis, 74, 1697, 10.1136/annrheumdis-2014-205348 Kloppenburg, 2016, Randomized, placebo-controlled trial to evaluate clinical efficacy and structure modifying properties of subcutaneous etanercept (ETN) in patients with erosive inflammatory hand osteoarthritis (OA), Ann Rheum Dis, 75, 90, 10.1136/annrheumdis-2016-eular.3663 Kroon, 2016, Effect of etanercept on synovitis and bone marrow lesions in erosive hand osteoarthritis, Ann Rheum Dis, 75, 91, 10.1136/annrheumdis-2016-eular.3627 Magnano, 2007, A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands, J Rheumatol, 34, 1323 Fioravanti, 2009, Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study, Rheumatol Int, 29, 961, 10.1007/s00296-009-0872-0 Chevalier, 2009, Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study, Arthritis Rheum, 61, 344, 10.1002/art.24096 Lohmander, 2005, A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis, Ann Rheum Dis, 64, 449, 10.1136/ard.2004.023572 Silverstein, 2000, Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study, J Am Med Assoc, 284, 1247, 10.1001/jama.284.10.1247 Schnitzer, 2015, A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee, Osteoarthritis Cartilage, 23, S8, 10.1016/j.joca.2014.10.003 Jonsson, 2016, Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain, Br J Clin Pharmacol, 81, 688, 10.1111/bcp.12850 Balanescu, 2014, Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial, Ann Rheum Dis, 73, 1665, 10.1136/annrheumdis-2012-203164 Brown, 2012, Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial, J Pain, 13, 790, 10.1016/j.jpain.2012.05.006 Brown, 2013, Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial, Arthritis Rheum, 65, 1795, 10.1002/art.37950 Ekman, 2011, Efficacy and safety of intravenous tanezumab in osteoarthritis hip and knee pain: comparison to placebo and naproxen in two phase III studies (NCT00830063 & NCT00863304), J Pain, 12, P55, 10.1016/j.jpain.2011.02.223 Lane, 2010, Tanezumab for the treatment of pain from osteoarthritis of the knee, N Engl J Med, 363, 1521, 10.1056/NEJMoa0901510 Maloney, 2016, Efficacy and safety of fasinumab for osteoarthritic pain in patients with moderate to severe osteoarthritis of the knees or hips [abstract], Arthritis Rheumatol, 68 Mayorga, 2013, Double-blind, randomized study to evaluate efficacy, and safety of fulranumab in patients with moderate to severe, chronic knee pain from osteoarthritis: Interim analysis results, J Pain, 4, S69, 10.1016/j.jpain.2013.01.615 Nagashima, 2011, Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study, Osteoarthritis Cartilage, 19, 1405, 10.1016/j.joca.2011.09.006 Sanga, 2013, Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain, Pain, 154, 1910, 10.1016/j.pain.2013.05.051 Schnitzer, 2015, Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain, Ann Rheum Dis, 74, 1202, 10.1136/annrheumdis-2013-204905 Spierings, 2013, A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee, Pain, 154, 1603, 10.1016/j.pain.2013.04.035 Tiseo, 2014, Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee, Pain, 155, 1245, 10.1016/j.pain.2014.03.018 Kortekaas, 2016, Brief report: association of inflammation with development of erosions in patients with hand osteoarthritis: a prospective ultrasonography study, Arthritis Rheumatol, 68, 392, 10.1002/art.39438 Mancarella, 2015, Ultrasound detected inflammation is associated with the development of new bone erosions in hand osteoarthritis: a longitudinal study over 3.9 years, Osteoarthritis Cartilage, 23, 1925, 10.1016/j.joca.2015.06.004 Xie, 2016, Economic and humanistic burden of osteoarthritis: a systematic review of large sample studies, Pharmacoeconomics, 34, 1087, 10.1007/s40273-016-0424-x Kingsbury, 2016, Hydroxychloroquine is not effective in reducing symptoms of hand osteoarthritis: results from a placebo-controlled randomised Trial [abstract], Arthritis Rheumatol, 68 Hill, 2011, Patients’ perceptions of the treatment and management of hand osteoarthritis: a focus group enquiry, Disabil Rehabil, 33, 1866, 10.3109/09638288.2010.550381 Lakhanpal, 2016, Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions, Clin Rheumatol, 35, 2869, 10.1007/s10067-016-3430-7 Holmes, 2012, Anti-NGF painkillers back on track?, Nat Rev Drug Discov, 11, 337, 10.1038/nrd3732 Hochberg, 2012, Adjudication of reported serious adverse joint events in the tanezumab clinical development program, Arthritis Rheum, 64, 260 Kumar, 2005 Smelter, 2013, New treatments for osteoarthritis, Curr Opin Rheumatol, 25, 310, 10.1097/BOR.0b013e32835f69b4 Ishikawa, 2015, Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis, Osteoarthritis Cartilage, 23, 925, 10.1016/j.joca.2015.02.002 Evans C.H. A phase I study evaluating the safety of intra-articular Sc-rAAV2.5IL-1Ra in subjects with moderate osteoarthritis of the knee (NCT02790723). 〈ClinicalTrials.gov〉 [Internet] Lubrano, 2016, Secukinumab for ankylosing spondylitis and psoriatic arthritis, Ther Clin Risk Manag, 12, 1587, 10.2147/TCRM.S100091 Dimitroulas, 2014, Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment, Semin Arthritis Rheum, 44, 145, 10.1016/j.semarthrit.2014.05.011